Comparative Pharmacology
Head-to-head clinical analysis: FERRLECIT versus FERUMOXYTOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRLECIT versus FERUMOXYTOL.
FERRLECIT vs FERUMOXYTOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric carboxymaltose, a polynuclear iron(III)-hydroxide carbohydrate complex, provides a source of iron for hemoglobin synthesis and erythropoiesis. The iron is released to endogenous iron transport proteins, such as transferrin, and stored as ferritin or hemosiderin.
Ferumoxytol is an ultrasmall superparamagnetic iron oxide nanoparticle that provides a source of iron for erythropoiesis. It is phagocytosed by macrophages of the reticuloendothelial system, and iron is released intracellularly to bind to transferrin and ferritin, replenishing iron stores.
125 mg elemental iron (5 mL) intravenously over 1-5 minutes or as infusion over 15-30 minutes, repeated as needed based on iron deficiency.
510 mg intravenously once, followed by 510 mg intravenously 3 to 8 days later for a total cumulative dose of 1020 mg. Administer as a slow IV injection at 1 mL/min (30 mg/min) undiluted or diluted in 50-200 mL normal saline.
None Documented
None Documented
Sodium ferric gluconate has a terminal half-life of approximately 1 hour for the intact complex. However, after dissociation, iron is rapidly cleared from plasma with a half-life of about 6 hours. The clinical context: the short half-life minimizes free iron toxicity but requires frequent dosing for iron replacement.
Terminal elimination half-life is approximately 14-21 hours in healthy adults; prolonged in patients with iron deficiency anemia (up to 30 hours) due to increased iron utilization.
Iron is not excreted renally; elimination is primarily through fecal loss of unabsorbed iron (approximately 80-90% of orally administered iron) and minor desquamation of mucosal cells. After IV administration, iron is incorporated into hemoglobin and storage pools; minimal urinary excretion (<1%). Biliary excretion of iron is negligible.
Ferumoxytol is eliminated primarily through the reticuloendothelial system, with the iron moiety incorporated into hemoglobin or stored as ferritin/hemosiderin. Minimal renal or biliary excretion of intact drug; <1% excreted unchanged in urine.
Category C
Category C
Iron Replacement
Iron Replacement